On Tuesday, December 12, 2023, CDER’s Office of Communication, Division of Drug Information (DDI) will host a webinar titled: FDA Drug Topics: An Overview of FDA’s Project Facilitate Oncology Expanded Access Program. Expanded access, sometimes called “compassionate use”, is a potential pathway for a
Stereotactic body radiation therapy (SBRT) for patients with operable stage I non-small cell lung cancer (NSCLC) is less invasive than surgery. However, differences in lifetime…
Heather Simonsen interviews Neli Ulrich, PhD, MS and Sach Apte, MD, MS, MBA about what it means to deliver a cancer-free frontier. Heather Simonsen interviews…
A cancer researcher’s unique lab @OSUCCC_James is studying the intersection of obesity and pancreatic disease to improve outcomes for pancreatic cancer.
Abstract. On December 1st, 2022, the FDA approved the new molecular entity olutasidenib (Rezlidhia: Rigel Pharmaceuticals), a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), for the…
August 3, 2023 | Virtual Meeting September 11, 2023 | Conference September 26, 2023 | Virtual Meeting November 14, 2023 | Conference
Journal publications by FDA oncology/hematology reviewers
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the…
A quarterly newsletter for patients living with cancer, survivors, advocates and consumers
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and…
